基于遗传学的进步,对抗药性的概述:一个队列研究
Betül Kılıç1, Yasemin Topçu1, Akif Ayaz2
1Department of Pediatric Neurology, Istanbul Medipol University Faculty of Medicine, Istanbul, Turkey.
Neurology India
|January 9, 2026
概括
基因检测,特别是全外体测序 (WES),显著提高了耐药性的诊断率. 这种方法对于针对性治疗和DRE患者的遗传咨询至关重要.
科学领域:
- 遗传学 是一个遗传学.
- 神经学 神经学
背景情况:
- 耐药性 (DRE) 有复杂的原因,遗传学在患者的一个子集中起作用.
- 基因技术的进步,如基因板和全外体序列 (WES) 提供了新的诊断和治疗途径.
研究的目的:
- 评估基因板和WES在识别DRE.的遗传原因方面的诊断实用性.
- 确定这些基因方法在DRE患者队列中的诊断收益率.
主要方法:
- 对3727起DRE案件进行了回顾性审查.
- 分析了116名接受TruSight One基因组测试的患者的遗传结果.
- 对413名接受全外因组测序 (WES) 的患者遗传发现的评估.
主要成果:
- 全外体测序 (WES) 在56.7% (234/413) 的DRE患者中发现了显著的致病突变.
- 基因组测试在47.4% (55/116) 的病例中产生了初步诊断.
- 病原性突变最常见于SCN1A,STXBP1和CDKL5基因,以及其他基因.
结论:
- 基因检测,特别是WES,大大增加了DRE的诊断率.
- 尽管临床特征重叠,但确切的遗传诊断对于避免不必要的测试,指导特定治疗和促进遗传咨询至关重要.
相关概念视频
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
Antiepileptic Drugs: Glutamate Antagonists
884
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
884
Antiepileptic Drugs: Potassium Channel Activators
624
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
624
Seizures: Classification
1.3K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.3K
Factors Affecting Drug Response: Overview
2.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.9K


